There are two specific aims of the NIH's grant, according to ThermoGenesis. The first aim is to prototype and manufacture in small quantities an enhanced X-Series cartridge. The second aim is to validate and optimize the performance of all steps of gene-engineered autologous cell therapy (GEAC) manufacturing in a single cartridge.
The company said it intends to apply for a phase II SBIR grant to design and validate the Quintessence instrument that will fully automate the specific workflow.
Copyright © 2021 scienceboard.net